US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Positive data from the clinical phase I MAD study with AlzeCure's Alzheimer's project NeuroRestore ACD856

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company has completed the clinical phase I study (multiple ascending dose, MAD) with repeated dosing of the drug candidate ACD856, with a focus on Alzheimer's disease.Data show that ACD856, the primary drug candidate within the company's NeuroRestore platform, has good tolerability and safety. Furthermore, the results demonstrate

AlzeCure presents at Redeye Life Science Day 2021 on November 11

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company is participating at Redeye Life Science Day 2021 on November 11 at 14:30 CEST, where CEO Martin Jönsson will present the company’s latest developments. The presentation will be followed by a Q&A with external experts on-site and Redeye's analysts.The presentation will be held in English and live streamed via https://www.redeye.se/events/

AlzeCure presents at Redeye Neurology (CNS) Seminar on October 13

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company is participating at Redeye Neurology (CNS) Seminar on October 13 at 10:55 CEST, where CSO Johan Sandin will present the company’s latest developments. The presentation will be followed by a panel discussion together with representatives from AlziNova and BioArctic and moderated by Redeye's analysts.The presentation will be held in English

AlzeCure Pharma develops novel analgesic drug based on Nobel prize-winning discoveries

Stockholm, Sweden, October 6, 2021. AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the its novel clinical candidate drug ACD440 for peripheral neuropathic pain, is based on the seminal discoveries of TRPV1 by Prof. Julius, and for which he was awarded the Nobel Prize in Medicine 2021.David Julius, PhD, professor and chair of the Department of Physiology and Morris Herzstein Chair in Molecular

New data showing the potential of the NeuroRestore project in depression presented at ECNP 2021 conference

Stockholm, Sweden, October 5, 2021. AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company’s presentation and poster regarding the research platform in neurology, NeuroRestore, its connection to BDNF/TrkB signaling and potential therapeutic role in depression, as presented at the European College of Neuropsychopharmacology (ECNP) 2021 on 2-5 October in Lisbon, Portugal, are now available in its

AlzeCure’s Alzheimer project has initiated the next clinical phase I study with ACD856

Stockholm, Sweden, October 4, 2021. AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the first participant has been dosed in the company’s next clinical phase I study (multiple ascending dose, MAD) with the candidate drug ACD856, focused on Alzheimer's disease.”It is satisfying that the clinical development program is proceeding according to plan and that we have now begun this follow-up phase I

AlzeCure presents at Vator Healthcare Innovation Summit on October 7

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company is participating at the Vator Healthcare Innovation Summit at Epicenter Stockholm on October 7 at 10:20 CEST, where CEO Martin Jönsson will present the company’s latest developments.The presentation will be live streamed and held in English. Register for the event at: https://vatorsecurities.se/event/vator-securities-healthcare-innovation-

AlzeCure presents at Naventus Life Science Summit on September 29

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company is participating at the Naventus Life Science Summit at Grand Hotel in Stockholm on September 29 at 09:25 CEST, where CEO Martin Jönsson will present the company’s latest developments.The event is organized by Naventus Corporate Finance together with Setterwalls, Deloitte, FNCA, Nordnet and Nasdaq. The presentation will be held in

AlzeCure’s Alzheimer’s project receives approval to start next clinical phase I study with ACD856

Stockholm, Sweden, August 30, 2021. AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company has received approval from the regulatory authorities in Sweden to begin the next clinical phase I study (multiple ascending dose, MAD) with the candidate drug ACD856 focused on Alzheimer's disease.The MAD Phase I study is AlzeCure's third clinical study with ACD856, the lead candidate drug within the

AlzeCure’s ACD856 demonstrates good tolerability in Phase I clinical trial and is approved for additional doses

Stockholm, Sweden, August 27, 2021. AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company has received approval from the Medical Products Agency to be able to give additional doses of ACD856 in the clinical phase I study (single ascending dose, SAD) with ACD856, as its good tolerability enables higher doses to be tested.Data from the SAD study establish that ACD856, the lead candidate drug

AlzeCure publishes its interim report for January – June 2021

Stockholm, Sweden, August 25, 2021. AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January – June 2021 is now available on the company’s website: www.alzecurepharma.se/en/section/investors/financial-reports/“The AlzeCure team continues to make good progress according to plan, in high-profile areas that are becoming increasingly relevant, such as the US Food and Drug Administration’s (FDA) approval of a new drug for Alzheimer’s disease, the first in 18 years, which is expected to boost interest in the Alzheimer’s field. During the second

AlzeCure gives live streamed strategy update on Alzheimer’s disease and NeuroRestore on September 1

Stockholm, Sweden, August 17, 2021. AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that it will give a live streamed update focusing on its project platform NeuroRestore and Alzheimer’s disease on September 1 at 09:00 CEST. The presentation will be followed by a Q&A session and discussion led by Fredrik Thor, analyst at Redeye.Martin Jönsson, CEO at AlzeCure, together with Johan Sandin, CSO, and Pontus

AlzeCure to present abstract at ECNP conference on NeuroRestore project's potential in depression

Stockholm, Swede, August 12, 2021. AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that an abstract about the neurology platform NeuroRestore, its link to BDNF/TrkB signalling and potential therapeutic role in depression, has been accepted for presentation at the ECNP 2021 conference, which this year will be held in Lisbon, Portugal, on October 2-5.The abstract, titled Characterization of positive

New data supporting targeting Trk receptors with ACD856 for the treatment of Alzheimer's disease presented at AAIC 2021

Stockholm, Sweden, July 29, 2021. AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company's presentation and poster regarding the clinical candidate drug ACD856 for Alzheimer's disease, presented at the Alzheimer's Association International Conference (AAIC) 2021 on July 26-30 in Denver, USA, are now available on the company's website.The abstract, titled ACD856 – a novel positive allosteric

AlzeCure publishes its interim report for January – September 2020

AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January – September 2020 is now available on the company’s website: https://www.alzecurepharma.se/en/section/investors/financial-reports/“AlzeCure has had another productive quarter during which its operations progressed according to plan, with advances in all three of our project platforms: NeuroRestore, Alzstatin and Painless. Preparations to begin two additional clinical trials at the end of the year for the drug candidates ACD856 and ACD440 are proceeding according to plan.” Martin

AlzeCure receives approval to start clinical Phase I trial with ACD856 in Alzheimer's disease

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company has received approval from the regulatory authorities in Sweden to initiate a clinical Phase I study with the drug candidate ACD856.The Phase I study is AlzeCure's second clinical study with ACD856, the lead drug candidate within the company’s NeuroRestore platform, which is developed as a symptom-relieving treatment for disease states

Poster presentation with the Alzstatin platform now available on AlzeCure's website

AlzeCure Pharma AB (publ) (FN STO: ALZCUR) (“AlzeCure”), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company's poster presentation and abstract about the Alzstatin platform, which was presented at the annual Alzheimer's conference CTAD, Clinical Trials in Alzheimer's Disease, on November 4-7, 2020, are now available in full on the company's website.The poster presentation, given by Johan Sandin, CSO at AlzeCure, presents how the

Poster presentation with ACD856 in Alzheimer's now available on AlzeCure's website

AlzeCure Pharma AB (publ) (FN STO: ALZCUR) (“AlzeCure”), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company's poster presentation and abstract about the drug candate ACD856, which was presented at the annual Alzheimer's conference CTAD, Clinical Trials in Alzheimer's Disease, on November 4-7, 2020, are now available in full on the company's website.The poster presentation, given by AlzeCure’s CSO Johan Sandin, shows that ACD856 has

AlzeCure gets abstract on the NeuroRestore platform against Alzheimer's accepted for poster presentation at CTAD

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company has received a second abstract approved for poster presentation at the annual Alzheimer's conference CTAD, Clinical Trials in Alzheimer's Disease, which this year will be held completely digitally on November 4-7.The abstract titled ACD856, a novel cognitive enhancer targeting neurotrophin signaling for the treatment of Alzheimer’s Disease

AlzeCure gets abstract on the Alzstatin platform against Alzheimer's accepted for poster presentation at CTAD

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company has received an abstract approved for poster presentation at the annual Alzheimer's conference CTAD, Clinical Trials in Alzheimer's Disease, which this year will be held completely digitally on November 4-7.The abstract, titled Gamma-secretase modulators show selectivity for gamma-secretase-mediated amyloid precursor protein intramembrane

AlzeCure publishes its interim report for January – June 2020

AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January – June 2020 is now available on the company’s website:  https://www.alzecurepharma.se/en/section/investors/financial-reports/“With yet another eventful quarter behind us we can conclude that AlzeCure’s operations are progressing well and according to plan, with continued advances in all of our three project platforms: NeuroRestore, Alzstatin and Painless. One important milestone that we achieved is the conclusion of a clinical trial for the NeuroRestore project ACD856, with positive

Vator Securities: No one-trick pony – advancing a novel platform-based CNS company

AlzeCure has with its seven-project portfolio multiple shots at goal where each, while early stage, represents a potential multibillion-dollar opportunity. It goes without saying that the past year’s achievements mark management’s extensive experience and competence in drug development and how to sophisticatedly run a research and development company. This is an important asset to recognize, and it should provide the market confidence in the company’s ability to drive the company successfully forward and limit the risk-profile to biological risk factors. By leveraging its solid

AlzeCure announces positive data from clinical study with ACD856

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company has received positive results from the first clinical study with ACD856, aiming to evaluate half-life in humans. ACD856 is currently under development for e.g. Alzheimer’s disease.The results demonstrate that ACD856, the lead drug candidate within the company's NeuroRestore platform, has a good pharmacokinetic profile with a significantly

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe